Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,551.22
(
-0.84%
)
US TECH 100
23,434.00
(
-1.21%
)
Dow Jones
45,799.33
(
-0.48%
)
Brent Oil
106.54
(
2.02%
)
Bitcoin
69,797.00
(
-0.15%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 137461

Tuesday, 02/21/2012 10:35:25 AM

Tuesday, February 21, 2012 10:35:25 AM

Post# of 257262
Enanta’s NS5A inhibitor (EDP-239) was announced 2 years ago (#msg-47301187), and there was nary a peep about it until now. NVS’ back-ended deal looks much more reasonable than what other HCV suitors have been doing lately.

Enanta is also the developer of ABT’s ABT-450 PI (#msg-61757048).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up